Clinical trial landscape for stem cells in autoimmune and inflammatory diseases: a comprehensive analysis and path forward.

Background: Autoimmune and inflammatory diseases present significant therapeutic challenges due to their chronic nature and limited response to conventional treatments. Stem cell-based therapies have emerged as a promising approach, leveraging their immunomodulatory and regenerative properties to address treatment-resistant cases. Methods: We conducted a comprehensive analysis of 1136 stem cell clinical trials from the TrialTrove database (October 2024), focusing on therapeutic efficacy, trial progression patterns, and geographic distribution. Key clinical outcomes and safety profiles were systematically evaluated. A choropleth map (Figure 1C) summarizes national activity across continents, with darker shading indicating more trials. Results: Stem cell trials showed substantial growth over two decades, increasing from 11 trials annually (2000-2004) to a peak of 73 trials in 2019. However, translation to late-phase studies remains limited, with only 10.2% of trials advancing to Phase III. Notable therapeutic successes include a 92.5% survival rate in systemic lupus erythematosus using umbilical cord mesenchymal stem cells and a 56.3% remission rate in Crohn's disease with adipose-derived mesenchymal stem cells versus 38.6% with placebo (P = 0.010). Safety analyses across 36 randomized controlled trials involving 2076 participants demonstrated favorable safety profiles. These dynamics are visualized in Figure 1A, using stacked bars by phase with a superimposed total line to highlight the 2019 inflection. The distribution by phase together with the current recruitment status is detailed in Figure 1B. Conclusions: Stem cell-based therapies demonstrate significant therapeutic potential for autoimmune and inflammatory diseases. To accelerate clinical translation, the field must address standardization challenges, enhance late-phase trial development, and establish robust regulatory frameworks. These efforts are essential for realizing the full therapeutic potential of stem cell therapies.